CYTOTOXIC THERAPY REVISED: EXPLORATION OF INNOVATIVE (PRO)DRUGS IN PATIENT-DERIVED XENOGRAFTS OF SOFT TISSUE SARCOMA KU Leuven
Soft tissue sarcomas (STS) represent a heterogeneous group of rare, malignant tumors of mesenchymal origin, which comprises more than 80 histological subtypes. Despite their extensive histological and molecular variety, the majority of STS are treated in a rather uniform way, especially in advanced setting. For these patients, doxorubicin has remained the first-line standard-of-care ever since its first introduction in the 1970s. However, ...